Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic.
about
Rifaximin for maintenance therapy in antibiotic-dependent pouchitisUse of rifaximin in gastrointestinal and liver diseasesInflammation: A novel target of current therapies for hepatic encephalopathy in liver cirrhosisEfficacy, safety, and applicability of outpatient treatment for diverticulitisPrevention of travelers' diarrhea with rifaximin in US travelers to MexicoRifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats.Small intestinal bacterial overgrowth: diagnosis and treatment.Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial.Italian consensus conference for colonic diverticulosis and diverticular disease.Impact of crystal polymorphism on the systemic bioavailability of rifaximin, an antibiotic acting locally in the gastrointestinal tract, in healthy volunteers.Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents.Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascitesRifaximin Is Effective for the Treatment of Clostridium difficile-Associated Diarrhea: Results of an Open-Label Pilot Study.Determination of rifaximin treatment period according to lactulose breath test values in nonconstipated irritable bowel syndrome subjects.Pathophysiology and Therapeutic Strategies for Symptomatic Uncomplicated Diverticular Disease of the Colon.Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases.Rifaximin is an effective alternative to metronidazole for the treatment of chronic enteropathy in dogs: a randomised trial.Advances in the management of colonic diverticulitis.Preventing recurrent acute diverticulitis with pharmacological therapiesA randomized, double-blind, placebo-controlled trial of rifaximin, a nonabsorbable antibiotic, in the treatment of tropical enteropathy.Pros and cons of antibiotic therapy for pouchitis.Pharmacotherapy of hepatic encephalopathy in cirrhosis.Treatment options for hepatic encephalopathy.The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis.Agents that act luminally to treat diarrhoea and constipation.Rifaximin: recent advances in gastroenterology and hepatologyRifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome.Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome.Rifaximin in the management of colonic diverticular disease.Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulationRosacea and gastrointestinal disorders: a population-based cohort study.Rifaximin Improves Clostridium difficile Toxin A-Induced Toxicity in Caco-2 Cells by the PXR-Dependent TLR4/MyD88/NF-κB PathwayTherapeutic Success of Rifaximin for Clostridium difficile Infection Refractory to Metronidazole and Vancomycin.Rifaximin therapy and hepatic encephalopathy: Pros and cons.Rifaximin for the treatment of hepatic encephalopathy.Rifaximin diminishes neutropenia following potentially lethal whole-body radiation.Microbial manipulation as primary therapy for Crohn's disease.Spontaneous bacterial peritonitis by Pasteurella multocida under treatment with rifaximin.Rifaximin, gut microbes and mucosal inflammation: unraveling a complex relationship.Metronidazole or Rifaximin for Treatment of Clostridium difficile in Pediatric Patients with Inflammatory Bowel Disease: A Randomized Clinical Trial.
P2860
Q21261868-6A680FF5-17AC-44F1-B02C-28213126F457Q26740201-FBE2B4C7-1527-4A63-B7F9-DCE5817B92EFQ26778000-A3C3C56A-409D-4A3E-8817-9C98E9C5FD16Q26862067-2C202411-2A87-49DB-91CD-42006FA458A5Q28280394-63AEC074-D910-4758-907E-A0A8F9D184C9Q31142368-5D83071F-E147-4FED-9EB8-7F5BB68193EFQ33438120-AFE2C1E6-9B12-431E-A70D-31BA98534557Q34409185-81601827-A3F5-43D4-B517-9FA05B9498C9Q34418890-F05A4282-76A2-42E6-987D-7165FCE71645Q34757166-E7D8D8A9-EA7B-4F3F-8AAE-070A9BDD6BBCQ35018460-2C578916-937B-4697-BDF9-A7E45E72E550Q35143004-69D97F09-6CEA-4A8C-931B-15559AFBB7C8Q35550741-E5DFB36E-F3E7-4BED-BD8F-D471391104D0Q35649153-1B48608F-5682-4D2F-9467-6B969CA8D157Q35803757-37DFC699-D1A6-40B6-878B-78B0C408A468Q35855737-5B63C229-E9FE-4B8D-A9E0-3B55E40DC6BFQ36157264-33E92B59-6B14-4F63-A2AF-802626FBF61EQ36247374-5FB924BE-7B8C-47FA-9C5C-729BDBD93383Q37253907-5CB7EE4C-3701-4D04-8968-27AE443761ECQ37378938-721B57AC-1ABF-41C7-B6CD-0173A59F073EQ37611860-D89C2D43-C86E-498D-98EE-8C36D6DDA281Q37729173-394AC2B0-E6CF-43EE-82C7-68059EEBF9E4Q37735854-79602D03-F2F4-4B82-8207-BDC9A6420782Q37951770-A77F231B-FDD3-41ED-A729-DFA5CF527E10Q38040321-203E43B6-7991-42D1-AEA3-F75A67D35055Q38074951-8772300B-DFDE-41F9-B883-DBEFB2112EC8Q38340085-D2030823-F814-4ECA-B4BC-5F1CD5C6E8A6Q38692607-36644D25-0D0B-4C0E-BC16-398EB310FEDEQ39295479-B42193A3-5140-44DB-AA51-C93242C2E2FDQ39455595-77BC8934-363C-466F-9D45-2EEDB660C00AQ39512887-4CC67AB6-101A-4BD8-AC4D-EEFC3C9CFDE5Q40652722-4E6D2072-8083-4D19-8C02-D20D1CD6634DQ41875708-9B1808F6-FA9F-4E9E-A6A8-9B3F257C85E6Q42324150-1F9D41AA-D977-448C-A2A4-9494AD527321Q42792218-25AC6D38-6713-47D3-A315-61FEC566BE50Q43013998-0703CF50-5838-4442-BF08-0B535C14117FQ43224619-F5592E4C-6FBA-4768-A3AC-C5EDE0EC8A8EQ44491619-29462B57-E7D8-41FF-AA2A-1EB18AD6C63EQ46835462-3F26AB70-7CD0-4504-A6BD-F29508E57D65Q47691053-615F4550-196A-4704-8A22-790A56CAC7B6
P2860
Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Experimental and clinical phar ...... testinal selective antibiotic.
@ast
Experimental and clinical phar ...... testinal selective antibiotic.
@en
type
label
Experimental and clinical phar ...... testinal selective antibiotic.
@ast
Experimental and clinical phar ...... testinal selective antibiotic.
@en
prefLabel
Experimental and clinical phar ...... testinal selective antibiotic.
@ast
Experimental and clinical phar ...... testinal selective antibiotic.
@en
P2860
P356
P1433
P1476
Experimental and clinical phar ...... testinal selective antibiotic.
@en
P2093
Carmelo Scarpignato
Iva Pelosini
P2860
P356
10.1159/000089776
P478
73 Suppl 1
P577
2006-02-08T00:00:00Z